#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	13008	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2084	617.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1411	1411	C	738	C	719	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23830	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	673.7	0	.	n	.	0	T695C	SNP	695	695	T	1039	1039	C	732	C,A,G	717,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23830	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	673.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1681	1681	A	749	A	733	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23830	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	673.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2315	2315	C	736	C,T	716,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23830	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	673.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2941	2941	T	693	T,C	675,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23830	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	673.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2389	2389	A	731	A,C	718,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1536	folP	852	852	100.0	folP.l15.c30.ctg.1	1731	88.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1154	1156	AGC	157;157;156	A;G;C	154;151;150	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4528	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3284	136.8	1	SNP	p	S91F	0	.	.	271	273	TCC	506	508	TCC	153;153;155	T;C;C	147;148;151	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4528	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3284	136.8	1	SNP	p	D95G	0	.	.	283	285	GAC	518	520	GAC	152;152;153	G;A;C	147;146;149	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4528	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3284	136.8	1	SNP	p	D95N	0	.	.	283	285	GAC	518	520	GAC	152;152;153	G;A;C	147;146;149	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1382	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1273	107.5	0	.	p	.	0	A39T	NONSYN	115	117	GCC	447	449	ACC	144;143;140	A,G,C;C;C	131,1,1;140;138	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1382	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1273	107.5	0	.	p	.	0	R44H	NONSYN	130	132	CGC	462	464	CAC	140;141;142	C;A,G;C	136;131,2;135	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1382	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1273	107.5	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	645	647	CAC	172;170;171	C,T;A;C	169,1;163;167	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1382	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1273	107.5	1	SNP	p	G45D	0	.	.	133	135	GGC	465	467	GGC	143;142;141	G;G;C	137;136;135	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	808	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1020	78.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	137.7	1	SNP	p	D86N	0	.	.	256	258	GAC	708	710	GAC	147;149;149	G;A;C	146;147;148	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	137.7	1	SNP	p	S87I	0	.	.	259	261	AGT	711	713	AGT	151;153;155	A;G;T	149;151;148	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	137.7	1	SNP	p	S87W	0	.	.	259	261	AGT	711	713	AGT	151;153;155	A;G;T	149;151;148	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	137.7	1	SNP	p	S87R	0	.	.	259	261	AGT	711	713	AGT	151;153;155	A;G;T	149;151;148	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4322	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	137.7	1	SNP	p	S88P	0	.	.	262	264	TCC	714	716	TCC	155;154;153	T;C;C	150;150;151	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3378	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2648	126.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1564	1566	GGC	153;149;145	G;G;C	149;146;139	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1293	1295	GCA	170;173;174	G;C;A	169;163;172	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1296	1298	ATC	176;174;174	A;T;C	173;171;172	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1308	1310	GTG	166;165;166	G;T,G;G	164;158,2;164	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1308	1310	GTG	166;165;166	G;T,G;G	164;158,2;164	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1812	1814	ACC	146;145;148	A;C;C	139;140;141	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1866	1868	GCG	154;154;155	G;C,G;G	146;132,2;147	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1866	1868	GCG	154;154;155	G;C,G;G	146;132,2;147	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1989	1991	GGC	138;137;135	G;G;C	135;133;130	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1998	2000	GGC	134;133;132	G;G;C	128;129;128	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3224	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2412	132.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2016	2018	CCG	104;108;106	C,G;C,G;G	99,1;100,1;96	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	527	4832	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3079	155.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1545	1547	CTG	186;185;180	C;T;G	176;173;171	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	527	4832	ponA	2397	100	97.0	ponA.l6.c30.ctg.2	343	1.4	0	.	p	.	0	T346P	NONSYN	1036	1038	ACC	288	290	CCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2238	porA	1146	1146	99.83	porA.l6.c17.ctg.1	1816	122.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	634	634	C	155	C,G	146,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	480	482	GGA	202;204;204	G;G;A	195;197;197	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	741	743	CTT	166;164;162	C,G;T;T,G	160,1;157;155,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	765	767	GGA	171;170;171	G,A;G,A;A	162,1;162,2;164	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	0	.	p	.	0	D171G	NONSYN	511	513	GAT	849	851	GGT	187;187;186	G;G;T,A	179;185;172,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	903	905	AGC	169;170;172	A;G;C,T	163;163;162,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	969	969	T	178	T	171	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	1	SNP	p	G120K	0	.	.	358	360	GGT	696	698	GGT	167;165;164	G;G;T	161;161;153	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	1	SNP	p	A121D	0	.	.	361	363	GCC	699	701	GCC	166;166;170	G;C;C	160;162;164	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2326	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1530	150.7	1	SNP	p	A121N	0	.	.	361	363	GCC	699	701	GCC	166;166;170	G;C;C	160;162;164	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8540	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4762	177.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1954	1956	AAT	185;183;184	A,C;A;T	183,1;182;180	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1050	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	978	106.4	1	SNP	p	V57M	1	.	.	169	171	ATG	509	511	ATG	236;236;234	A;T;G	232;227;227	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
